<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602390</url>
  </required_header>
  <id_info>
    <org_study_id>ANK-700-01</org_study_id>
    <nct_id>NCT04602390</nct_id>
  </id_info>
  <brief_title>Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis</brief_title>
  <acronym>MoveS-it</acronym>
  <official_title>A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anokion SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anokion SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study&#xD;
      has two parts:&#xD;
&#xD;
      Part A - first in human study in which patients receive a single dose of ANK-700 Part B -&#xD;
      patients will receive three doses of either ANK-700 or placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study ANK-700-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of&#xD;
      ANK-700 in patients with relapsing remitting multiple sclerosis (rrms).&#xD;
&#xD;
      An overview of the two parts and proposed dose groups is given below:&#xD;
&#xD;
      Part A (SAD): Patients will receive a single dose of ANK-700. Part B (MAD): Patients will&#xD;
      receive three doses of either ANK-700 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 or higher</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC last)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ANK-700 SAD Cohort 1, Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of ANK-700 Dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANK-700 SAD Cohort 2, Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of ANK-700 Dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANK-700 SAD Cohort 3 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive one dose of ANK-700 Dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 4 ANK-700 Dose A or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive three doses of ANK-700 Dose A or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 5 ANK-700 Dose B or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive three doses of ANK-700 Dose B or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANK-700</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>ANK-700 SAD Cohort 1, Dose A</arm_group_label>
    <arm_group_label>ANK-700 SAD Cohort 2, Dose B</arm_group_label>
    <arm_group_label>ANK-700 SAD Cohort 3 Dose C</arm_group_label>
    <arm_group_label>MAD Cohort 4 ANK-700 Dose A or Placebo</arm_group_label>
    <arm_group_label>MAD Cohort 5 ANK-700 Dose B or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>MAD Cohort 4 ANK-700 Dose A or Placebo</arm_group_label>
    <arm_group_label>MAD Cohort 5 ANK-700 Dose B or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at&#xD;
             screening&#xD;
&#xD;
          -  Neurologically stable with no evidence of relapse within the 28 days before signing&#xD;
             the informed consent form (ICF)&#xD;
&#xD;
          -  Either not currently receiving disease modifying MS therapy, or currently using&#xD;
             fumarate drugs (dimethyl fumarate or diroximel fumarate)&#xD;
&#xD;
          -  Patients must use a highly effective method of birth control or are sterile or&#xD;
             postmenopausal as confirmed by study Investigator&#xD;
&#xD;
          -  Patient has signed and understands the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary progressive MS or secondary progressive MS&#xD;
&#xD;
          -  Uncontrolled or significant medical conditions (including active infection or chronic&#xD;
             hepatitis) which, in the opinion of the Investigator, preclude participation&#xD;
&#xD;
          -  Patients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic&#xD;
             hormone, β-interferon, plasma exchange, fingolimod, ozanimod, or siponimod within the&#xD;
             3 months prior to first dose&#xD;
&#xD;
          -  Patients treated with cytotoxic agents (including, but not limited to, cladribine,&#xD;
             mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod,&#xD;
             teriflunomide, or IV gamma globulin within 12 months prior to first dose&#xD;
&#xD;
          -  Patients treated with monoclonal antibody therapy (including natalizumab, daclizumab,&#xD;
             rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose&#xD;
&#xD;
          -  Patients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal&#xD;
             stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies&#xD;
             for MS&#xD;
&#xD;
          -  Contraindication to or inability to undergo gadolinium-enhanced magnetic resonance&#xD;
             imaging (MRI) scan&#xD;
&#xD;
          -  Use of any investigational drug or experimental procedure within previous 6 months&#xD;
             that would interfere with the assessment of ANK-700&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anokion US, Inc</last_name>
    <phone>+1 857-320-6607</phone>
    <email>clinicaltrials@anokion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Health Neurosciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Parra Gonzalez</last_name>
      <email>jose.parragonzalez@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Piquet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Tardivo</last_name>
      <email>tardivl@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson University Hospitals</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angira Mathur</last_name>
      <email>angira.mathur@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas P Leist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Institute</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Hunter, MD</last_name>
      <phone>615-791-5470</phone>
      <email>FrontOffice@neurosci.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Quance</last_name>
      <email>Taylor.Quance@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Jemelka</last_name>
      <email>James.R.Jemelka@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>John W Lindsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Stigger</last_name>
      <email>tstigger@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Stacy Donlon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>relapsing remitting ms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

